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1. Introduction
The p53 tumour suppressor protein is one of the most 
celebrated proteins because of its status as “guardian of the 
genome” (Vogelstein et al 2000). It constitutes the central 
node in a network of molecular interactions regulating the 
cellular response to stresses like DNA damage and oncogene 
activation. These stresses promote tumour formation, often 
culminating in cancer. The chief role of p53 is to guard 
cells against malignant transformation. When the cellular 
DNA is damaged by ionizing radiation or chemical agents, 
the appropriate p53-mediated pathways are activated. This 
results in the arrest of the cell division cycle which prevents 
the proliferation of cells containing damaged DNA (tumour 
formation). In the next step, the biochemical processes 
involved in DNA repair are initiated. Once this task is 
completed successfully, the cell resumes its progression so 
that cell division can take place. If repair is not possible due 
to excessive damage, the p53-mediated apoptotic pathway 
becomes functional, leading to apoptosis, i.e. programmed 
cell death. 
The p53 activity is kept low in normal cells so that the 
cell cycle is not disrupted or the cell does not undergo 
untimely death. This is achieved through the operation of 
a negative feedback loop consisting of the p53 and MDM2 
genes (Ma et al 2005). The p53 protein functions as a 
transcription factor (TF) and regulates the expression of 
several target genes. This is achieved through the binding 
of the p53 at the regulatory region of the target DNA. The 
MDM2 gene is one of the target genes the transcription 
of which is activated by the p53 proteins. The MDM2 
proteins, however, inhibit the p53 activity, thus giving 
rise to a negative feedback loop. The ability of MDM2 to 
keep p53 in check is essential for normal cell function. The 
repression operates via three mechanisms. Firstly, MDM2 
binds p53 at its DNA binding domain so that the latter 
cannot function as a TF. Secondly, MDM2 on binding p53 
labels it for degradation and lastly, MDM2 is responsible 
for the export of p53 from the nucleus to the cytoplasm 
abrogating, in the process, its transcriptional activity. In 
mammalian cells, on DNA damage, a protein called ATM 
kinase is activated which phosphorylates the p53 protein at 
a specifi c site preventing the binding of the MDM2 protein 
to the p53 (Ghosh and Bose 2005). In the absence of MDM2 
mediated degradation of the p53, the protein stabilizes at a 
higher level, i.e. is in the ‘active’ state. The vital role of the 
p53 protein in maintaining cellular integrity is underscored 
by the fact that the p53 gene is mutated in about 50% of 
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human cancers. Systems biology approaches based on 
mathematical modelling provide signifi cant insight on the 
operational aspects of the p53 mediated pathways. In this 
paper, we describe the mathematical models developed by 
us to study the p53-mediated cell cycle arrest and apoptosis. 
We discuss briefl y the major results obtained and point out 
their experimental relevance.
2. Cell cycle arrest
The cell cycle is a sequence of orderly events during 
which a growing cell duplicates all its components so that 
after cell division each daughter cell has the same cellular 
constituents as the parent cell (Alberts et al 2002). In an 
eukaryotic organism, the cell cycle progresses through 
four distinct phases: G
1
, S, G
2
 and M (mitotic) phases. The 
division of the parent cell into two daughter cells occurs in 
the M phase. The eukaryotic cell cycle operates through the 
sequential activation and deactivation of cyclin dependent 
protein kinases (CDKs). Protein kinases are enzymes which 
regulate the structure and/or the activity of target proteins 
by the transfer of phosphate molecules (phosphorylation). 
Similarly, protein phosphatases regulate biochemical activity 
by removing phosphate molecules from target molecules 
(dephosphorylation). CDK activation can occur only after 
a regulatory protein cyclin binds CDK and the complex is 
phosphorylated by CDK-activating kinases (CAKs). Even 
if these conditions are met, the CDK may be inactivated 
by inhibitory phosphorylation carried out by certain 
protein kinases. Protein phosphatases remove the inhibitory 
phosphate molecules so that the activity of the cyclin-CDK 
complex is triggered. A cycle of synthesis and degradation 
of cyclins in each cell cycle controls the periodic assembly 
and activation of the cyclin-CDK complex. In higher 
eukaryotic organisms, different cyclin-CDK complexes 
initiate different cell cycle events. The cell control system, 
however, operates on similar principles which may thus be 
assumed to be universal. 
In the case of DNA damage by radiation or chemicals, 
the cell cycle is arrested at the damage checkpoints in the 
G
1
 and G
2 
phases. We have developed a mathematical model 
of the DNA damage checkpoint in the G
2
 phase of frog egg 
and mammalian cell cycles (Ghosh and Bose 2005). The 
activation of the checkpoint arrests the cell cycle transition 
from the G
2
 to the M phase. The active cyclin-CDK complex 
phoshorylates key intracellular proteins which in turn 
initiate or control important cell cycle events. The kinase 
Wee1 suppresses the activity of the cyclin-CDK complex 
through inhibitory phosphorylation. The active cyclin CDK 
complex, on the other hand, inactivates its antagonist, the 
kinase Wee1 (fi gure 1). One thus has an effective positive 
feedback loop involving Wee1 and the cyclin-CDK complex. 
The phosphatase Cdc25C removes the inhibitory phosphate 
group from the inactive cyclin-CDK complex converting 
it into the active form. The active cyclin-CDK complex 
activates its friend Cdc25C, giving rise to another positive 
feedback loop. The combination of positive feedback loops 
and nonlinearity in the dynamics of the system give rise 
to bistability in a range of parameter values (Novak and 
Tyson 1993, 2003; Tyson et al 2001). The two stable steady 
states correspond to the G
2
 (low activity of the cyclin-CDK 
complex) and the M (high activity of the cyclin-CDK 
complex) phases, respectively. The transition from the lower 
to the upper state occurs when the cyclin threshold crosses 
a critical value. Since the amount of cyclin is correlated 
with the cell size or cell mass/DNA, the latter quantity can 
be treated as the parameter the changing of which triggers 
the G
2
/M transition. Experimental evidence for hysteresis 
has recently been obtained in a frog egg extract confi rming 
earlier theoretical predictions (Sha et al 2003). 
The cell cycle is an example of a dynamical system 
in which events unfold as a function of time. The time 
evolution of the system is described in terms of a set of 
differential equations. Each different equation is a rate 
equation which has the form
where x is the amount of one type of biomolecule, say, 
active Cdc25C. The “gain” (“loss”) terms describe processes 
which increase (decrease) the amount . In the case of active 
Cdc25C, x is increased when active cyclin-CDK complex 
phosphorylates inactive Cdc25C into the active form. The 
amount x is decreased due to the conversion of the active 
Cdc25C into the inactive form (fi gure 1). In the case of the 
G
2
/M transition, one writes down a differential equation 
for each of the key biomolecules namely, active/inactive 
cyclin-CDK complex, Wee1 and Cdc25C. The mathematical 
expressions for the “gain” and “loss” terms on the RHS 
(right hand side) of eq. (1) are derived on the basis of 
standard chemical kinetic schemes (law of mass action, 
Figure 1. Molecular interactions of the cyclin-CDK complex 
with Weel and Cdc25C.
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Michaelis-Menten kinetics etc.). The reaction scheme shown 
in fi gure 1 leads to the following differential equations.
where x
1
 (x
2
) denotes the concentration of the active 
(inactive) cyclin-CDK complex, y is the concentration of 
the active Wee1 and z (z
1
) denotes the concentration of the 
active (inactive) Cdc25C. The total concentration of Wee1 is 
normalized to one so that 1 – y represents the concentration 
of the inactive Wee1. The j
i
’s (i = 1,....,6) are the Michaelis-
Menten constants. The fi rst term in eq. (2) describes the 
synthesis of cyclin, the rate of which is proportional to the 
cell mass/DNA m. In the G
2
 phase, cells are growing and 
larger cells, it is assumed, synthesize cyclin at a higher rate. 
The steady state solutions of eqs (2)–(6)       are obtained 
with the help of Mathematica. Figure 2 shows the result in 
the form of a hysteresis loop with m playing the role of the 
bifurcation parameter. In the region of bistability, the two 
stable steady states correspond to the G
2
 (lower branch) 
and M phases (upper branch) respectively. When m and 
correspondingly the cyclin concentration in the cyclin-CDK 
complex reaches a threshold value, the active complex 
inactivates Wee1 and activates Cdc25C in suffi cient 
amounts. This triggers the autocatalytic conversion of the 
inactive cyclin-CDK complex into the active complex and a 
transition to the mitotic phase, with a higher concentration 
of the active cyclin-CDK complex, takes place.The results 
shown in fi gure 2 have been obtained for the following 
parameter values. The rate constants in appropriate units are 
j
c
=2, k = 1, k
1
=1, γ
c1
=1, γ
c2 
=1, k
2
=0.4, k′
2 
= 2, k
3 
= 0.4, k′
3 
= 
0.1, α = 1, β
1 
= 0.4. The Michaelis-Menten constants are: j
3 
= 
0.02, j
4 
= 0.02, j
5 
= 0.02, j
6 
= 0.02. Values of the different rate 
and Michaelis-Menten constants are consistent with those 
reported in earlier literature.
We now discuss the arrest of the cell cycle on DNA 
damage. The DNA damage response network is shown 
in fi gure 3. Recently, Lahav et al (2004) have performed 
single cell experiments on the dynamics of the network after 
DNA damage. The response of the network to the damage 
is found to be digital in the form of a discrete number of 
p53 and MDM2 protein pulses. As already mentioned, the 
p53-MDM2 network can be described in terms of a negative 
feedback loop. The simple motif can give rise to oscillations 
if the number of elements in the loop exceeds two or a time 
delay is included in the feedback process. A mathematical 
model of the p53-MDM2 negative feedback loop included an 
intermediary of unknown origin in order to obtain oscillations 
(Lev Bar-Or et al 2000). A later study proposed that the 
p53-MDM2 network includes both positive and negative 
Figure 2. Hysteresis loop for the G
2
/M transistion; x
1 
is the steady 
state concentration of the active cyclin-CDK complex and m the 
cellular mass/DNA.
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Figure 3. DNA damage response network leading to cell cycle 
arrest.
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feedback loops (Ciliberto et al 2005). The indirect inhibition 
of MDM2 by p53 in the positive feedback loop occurs via 
the interactions involving PTEN, PIP3 and Akt. The negative 
feedback loop also includes certain intermediate processes. 
It has been suggested that the intermediate processes in both 
the positive and negative feedback loops give rise to the time 
delay required for obtaining the MDM2 oscillations. We 
have proposed a simplifi ed scheme in which oscillations are 
generated by considering the expression of the MDM2 gene 
to be a two step process, i.e. consisting of both transcription 
and translation. In the earlier modelling studies, only one 
step, namely, protein synthesis was taken into account. The 
two-step gene expression introduces a time delay in the p53-
MDM2 network dynamics leading to oscillations (fi gure 4). 
The same result is obtained if time delay in the expression of 
both the p53 and MDM2 genes, via the two-step processes of 
transcription and translation, is considered. In our model, the 
pulses are obtained in the absence of the p53-MDM2 positive 
feedback loop provided the amount of DNA damage exceeds 
a threshold value. In the presence of the positive feedback 
loop, the magnitude of the threshold is lowered, i.e. the 
response occurs for a smaller amount of damage. The DNA 
damage response network in fi gure 3 shows that the arrest 
of the G
2
/M transition can occur via two pathways: either 
through the inhibition of Cdc25C activity by the chk1 kinase 
or via the inhibition of the cyclin-CDK complex activity 
by p21 proteins. The p53 pulses activate the transcription 
of the p21 gene. The differential equations describing the 
time evolution of the combined networks shown in fi gures 
1 and 3 can be written down following standard procedure 
(Ghosh and Bose 2005). The solution of the equations yields 
interesting results. Figure 5 shows that the cell cycle is 
arrested (compare with fi gure 2) on DNA damage when the 
copy number of the p53 gene is two. The arrest implies a 
time delay in the transition from the G
2
 to the M phase of the 
cell cycle. The delay increases, though not signifi cantly, with 
increasing DNA damage. Eukaryotes are diploid organisms 
in which each gene has two identical copies. Knudson’s 
well-known two hit model of tumourigenesis suggests that 
mutation in both copies (diploid organisms have two copies 
of each gene) of a tumour suppressor gene is essential for 
triggering tumour formation (Knudson 1971; Fodde and 
Smits 2002; Hohenstein 2004). Recent studies, however, 
show that the mutation of a single copy is suffi cient in many 
cases for the loss of tumour suppression function of p53 
protein. The gene dosage effect is called haploinsuffi ciency 
(HI) and has been verifi ed experimentally (Venkatachalam 
et al 1998; Song et al 1999). Tumours are found to arise in 
mice with only one intact copy of the p53 gene contrary to 
Knudson’s hypothesis. Our model calculations show that 
the G
2
/M transition is nor arrested when the copy number 
of the p53 gene is one. This results in a proliferation of cells 
containing damaged DNA which may result in cancer. The 
key theoretical predictions are, however, yet to be verifi ed 
in an experiment which explicitly confi rms the underlying 
mechanism based on bistability.
3. Proliferation versus death
MDM2, the biological regulator of p53, is found to be 
overexpressed in certain types of cancer (Tovar et al 
2006). The origin of increased gene expression lies in 
gene amplifi cation or enhanced rates of transcription and 
translation. Since MDM2 is a negative regulator of p53 
activity, the overproduction of MDM2 proteins gives rise to a 
greater risk in the development of malignancy. To counteract 
this, one strategy is to use small-molecule inhibitors to block 
the protein-protein interaction of MDM2 and p53. Vassilev 
and coworkers (Vassilev et al 2004; Tovar et al 2006) have 
developed a class of small molecules known as nutlins which 
occupy the p53 binding pocket in MDM2, thus preventing 
the binding of MDM2 to p53 and facilitating the activation 
of the p53 pathways in human cancer cell lines. The effi cacy 
of the strategy has been demonstrated in experiments paving 
Figure 4. Pulses of p53 proteins generated on DNA damage; p is 
the total p53 concentration.
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Figure 5. Cell cycle arrest on DNA damage; x
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mass/DNA.
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the way for the use of nutlins as an anticancer drug. Vassilev 
et al (2004) selected a panel of 10 cell lines, derived from 
different human tumours, for their experiments. In all the 
cell lines, the p53 genes are not mutated. In the osteosarcoma 
(SJSA-1) cell line, the MDM2 gene is amplifi ed 25-fold 
whereas all the other cell lines have a single copy of the 
MDM2 gene. Exponentially growing cells in all the cancer 
cell lines were treated with nutlin-3 for several hours. The 
cell cycle progression was found to be arrested in all the 
cell lines. The apoptotic response, however, was signifi cant 
(~ 80%) only in SJSA-1, i.e. in the case of MDM2 
overexpression. The response was low in the other cell lines, 
e.g. <10% in HCT116 (colorectal cancer). A high apoptotic 
response was also obtained in a second osteosarcoma cell 
line (MHM) with an ≈ 10-fold amplifi cation of the MDM2 
gene. We have developed a mathematical model to explore 
the possible origin of the considerable difference in the 
apoptotic response of cancer cell lines, with and without 
MDM2 overexpression, when subjected to nutlin-3 
treatment. Some aspects of the model are similar to those 
of earlier mathematical models of the apoptotic pathways 
(Fussenegger et al 2000; Bagci et al 2006). In the following, 
we give a brief description of the major results obtained. 
A fuller account of the study will be published elsewhere 
(Ghosh B and Bose I, unpublished results). 
Figure 6a shows a schematic diagram of the p53-mediated 
apoptotic pathway which is activated when the p53-MDM2 
interaction is inhibited by nutlin molecules. The p53 proteins 
upregulate the synthesis of the pro-apoptotic Bax proteins 
and downregulate that of the anti-apoptotic Bcl-2 proteins 
(Fussenegger et al 2000; Hengartner 2000; Bagci et al 2006; 
Ghosh B and Bose I, unpublished results). The Bcl-2 binds 
the Bax protein to form a heterodimer and consequently 
suppress the pro-apoptotic activity of Bax. The Bcl-2 further 
binds the apoptotic protease-activity factor 1 (Apaf-1) and 
thereby excludes the binding of procaspase-9 to Apaf-1. The 
Bax and other pro-apoptotic proteins help in the release of 
cytochrome c proteins from the mitochondria. Apaf-1 binds 
cytochrome c to form the apoptosome complex which in turn 
binds procaspase-9. A family of proteases termed caspases 
play a central role in bringing about apoptosis. The blocking 
of caspase activity can slow down or prevent apoptosis. 
Caspases selectively cleave a set of specifi c target proteins 
at one or a few positions, always after an aspartate residue. 
The cleavage results in non-functional target proteins. The 
binding of the procaspase-9 to the apoptosome leads to 
initiator caspase-9 activation through cleavage of the bound 
procaspase-9. The initiator caspases activate the executioner 
or effector caspases. This is followed by the cleavage of 
procaspase-3 to yield the active effector molecule, caspase-
3. Executioner caspases like caspase-3 cleave key cellular 
proteins and dismantle the cell resulting in apoptosis. 
The end comes provided the executioner caspases such 
as caspase-3 are activated to suffi ciently high levels. The 
level of activation depends on the competition between the 
pro- and anti-apoptotic agents/processes constituting the 
apoptotic pathway shown in fi gure 6a. We have retained 
only the key components in the p53-mediated apoptotic 
network which in reality is quite complex. The apoptotic 
network further includes two important processes, namely, 
the cleavage of the anti-apoptotic Bcl-2 by caspase-3 and the 
inhibition of the processing and activation of procaspase-3 
Figure 6. (a) The p53-mediated apoptotic pathway. (b) the subnetwork of regulatory interactions between p53, MDM2 and p21. The 
dotted link in (a) includes the subnetwork shown in (b).
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by p21. These two processes provide direct links between 
the events upstream and downstream of cytochrome c 
release. There is now increasing evidence that p21 has a 
dual role in the p53-MDM2 network of a number of systems 
(Gartel and Tyner 2000; Dotto 2000). The p21 protein levels 
are activated under cellular stress due to the activation of 
p53 proteins. The protein helps in the arrest of the cell 
cycle and may also have the dual function of protecting 
cells against apoptosis. Figure 6b shows some additional 
biochemical processes incorporated in the p53-MDM2 
network of our model to study apoptosis. One of these 
relates to the observation that MDM2 is a negative regulator 
of p21 independent of p53. The physical interaction between 
p21 and MDM2, leading to the binding of the proteins both 
in vitro and in vivo, has been demonstrated in experiments 
(Zhang et al 2004). MDM2 promotes p21 degradation by 
facilitating the binding of a proteasomal subunit. Thus, 
MDM2 overexpression gives rise to lower p21 protein 
levels. Experiments on the HCT116 human colorectal cancer 
cells (one of the cell lines in Vassilev et al’s experiment) 
show that the p53 levels are enhanced with abolition of the 
p21 gene expression (Javelaud and Besançon 2000). In fact, 
the Bax/Bcl-2 ratio has been found to be 4-fold higher in the 
absence of p21 proteins. A higher Bax/Bcl-2 ratio tilts the 
balance in the favour of apoptosis. Disruption of p21 activity 
leads to enhanced p14Arf expression. The p14 proteins are 
antagonistic to the MDM2 activity so that p53 proteins can 
accumulate to higher levels.
In the mathematical model describing the p53-mediated 
apoptotic pathway (fi gure 6), the time evolution of the 
system can again be represented by a set of coupled 
differential equations (Ghosh B and Bose I, unpublished 
results). The steady state solutions of the equations for 
different parameter values are obtained numerically. Figure 
7 shows a generalised plot of the steady state amount of 
caspase-3 versus the amounts of p53 and p21. The latter two 
concentrations are treated as independent variables. In the 
steady state of the p53-MDM2 network shown in fi gure 6b, 
the concentrations of the p53 and p21 proteins can vary over 
wide ranges depending on the magnitudes of the different 
parameters of the network. The latter include various rate 
and binding constants, the basal expression levels and the 
gene copy number of, say, the MDM2 gene. These quantities 
have values which are often cell and tissue-specifi c so that 
diverse combinations of the steady state concentrations of 
p53 and p21 are possible. The dotted link between p53 and 
p21 in fi gure 6a includes the subnetwork shown in fi gure 
6b. The plot in fi gure 7 is obtained with the p53 and p21 
proteins serving as independent inputs to the apoptotic 
pathway in fi gure 6a. The two protein amounts are given 
by the respective concentrations in the steady state of the 
subnetwork shown in fi gure 6b. The apoptotic pathway has 
a comparatively slower dynamics so that the p53-MDM2 
subnetwork reaches the steady state earlier. The goal is 
to study caspase-3 activation as a function of the p53 and 
p21 protein concentrations. The plot in fi gure 7 indicates 
a threshold-type activation of the caspase-3 level. We now 
focus attention on the two cancer cell lines, SJSA-1 (MDM2 
overexpressed) and HCT116 (MDM2 not overexpressed). 
In both the cases, the steady state concentrations of the p53 
and p21 proteins are determined from the set of differential 
equations governing the time evolution of the subnetwork 
shown in fi gure 6b. In the case of SJSA-1 cells, the level 
of p21 is found to be low since the degradation of p21 is 
enhanced due to an overexpression of the MDM2 proteins 
(Ghosh B and Bose I, unpublished results). The negative 
infl uence of p21 on the p53 and caspase-3 levels is less 
prominent in this case. From the generalized plot, one 
fi nds that the caspase-3 level, for the specifi c steady state 
amounts of p53 and p21, is suffi ciently activated so that 
apoptosis is possible. In the case of HCT116, the p21 level 
is high due to the lesser amount of degradation by MDM2 
so that apoptosis is not favoured. We have also modeled the 
activation of p53 on treatment with nutlin and fi nd that the 
cell cycle is arrested in both the SJSA-1 and HCT116 cells 
(Ghosh B and Bose I, unpublished results). 
In summary, we have described the salient features of 
our modelling studies on the p53-MDM2 network from a 
systems biology perspective. We have shown that the cell 
cycle is not arrested on DNA damage when the copy number 
of the p53 tumour suppressor gene is reduced from two to 
one. This prediction could be tested in an appropriately 
designed experiment. We have further shown that the 
experimentally observed p53 and MDM2 oscillations can be 
explained on the basis of time delay caused by the two-step 
nature (transcription and translation) of gene expression. 
The importance of time delay in the functional response 
of the p53-MDM2 network has been pointed out in some 
related studies (Tiana et al 2002; Wagner et al 2005). 
Figure 7. Steady state concentration of caspase-3 versus p53 and 
p221 amounts. The letter two proteins serve as independent inputs 
to the apoptotic pathway shown in fi gure 6a.
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There is a marked difference in the apoptotic response of 
cancer cells with normal MDM2 expression and MDM2 
overexpression when treated with nutlin, an inhibitor of 
the p53-MDM2 interaction. A possible explanation of the 
observed difference has been put forward in the framework 
of a mathematical model. The model shows a threshold-
type activation of the caspase-3 level as a function of 
p53 and p21 levels. Low levels of caspase-3 cannot bring 
about cell death. The amount of p21, the transcription of 
which is activated by p53, appears to be a crucial factor in 
determining the cell fate. The transcription of the p21 gene 
is activated by p53 proteins whereas the MDM2 proteins 
promote the degradation of the p21. The p21 has a negative 
effect on both the p53 and caspase-3 levels. If the p53 level 
is low, the ratio of the amounts of Bax and Bcl-2 proteins 
is not suffi ciently high to favour the release of cytochrome 
c from the mitochondria. The activation of the caspase-3 
level is hence minimal. Some of the ideas put forward can 
be tested experimentally by varying the p21 levels in cancer 
cells like SJSA-1 and HCT116 during nutlin treatment. 
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